滤泡辅助T细胞表型预测复发/难治性外周T细胞淋巴瘤对组蛋白去乙酰化酶抑制剂的反应
该回顾性研究分析了127例接受HDACi治疗的复发/难治性AITL或PTCL-NOS患者,重新审查病理以识别TFH表型。结果支持HDACi在TFH-PTCL中可能具有更优活性。
要点
- TFH表型是HDACi治疗复发/难治性PTCL后ORR的独立预测因素。
- TFH表型患者ORR 56.5%(CR 28.9%),非TFH 29.4%(CR 19.6%)。
- 部分PTCL-NOS具有TFH表型或可重新分类为AITL。
核心结论
- HDACi单药或联合治疗在TFH-PTCL中可能比非TFH PTCL具有更优活性。
研究设计与样本
- 回顾性分析127例复发/难治性AITL或PTCL-NOS患者,接受HDACi单药(97例)或联合(30例)治疗,并重新审查PTCL-NOS病理以识别TFH表型。
主要发现
- 16例对HDACi或联合治疗充分反应后直接进行异基因移植,其中1例对供者淋巴细胞输注有反应(12例TFH,4例非TFH)。
关键数值与推荐
- 7例PTCL-NOS具有TFH表型;2例PTCL-NOS被重新分类为AITL。
临床怎么用
- TFH表型可能有助于指导亚型特异性治疗选择及HDACi临床试验解读。
局限性
- 研究为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histone deacetylase inhibitors (HDACi) are active agents for peripheral T-cell lymphoma (PTCL). Anecdotally angioimmunoblastic T-cell lymphoma (AITL) appears to respond better than PTCL-not otherwise specified (NOS) to HDACi. The new World Health Organization classification shows that a subgroup of PTCL carries similarities in phenotype and gene expression profiling to AITL, comparable to T follicular helper (TFH) cells. The disease might behave similarly to AITL when treated with HDACi. We analyzed 127 patients with AITL or PTCL-NOS treated with HDACi at relapse as a single agent or in combination. We re-reviewed the pathology of all PTCL-NOS to identify the TFH phenotype. Patients received HDACi at relapse as a single agent in 97 cases (76%, 59 TFH, 38 non-TFH) or in combination in 30 cases (24%, 18 TFH, 12 non-TFH) including duvelisib, lenalidomide, lenalidomide plus carfilzomib, and pralatrexate. Seven PTCL-NOS had TFH phenotype; 2 PTCL-NOS were reclassified as AITL. Overall response rate (ORR) was 56.5% (28.9% complete response [CR]) in TFH and 29.4% (19.6% CR) in non-TFH phenotype patients (P = .0035), with TFH phenotype being an independent predictor of ORR (P = .009). Sixteen patients sufficiently responded to HDACi or HDACi in combination with another agent to proceed directly to allogeneic transplantation; 1 of 16 responded to donor lymphocyte infusion (12 TFH, 4 non-TFH). Our results, although retrospective, support that HDACi, as a single agent or in combination, may have superior activity in TFH-PTCL compared with non-TFH PTCL. This differential efficacy could help inform subtype-specific therapy and guide interpretation of HDACi trials.
引用
- Ghione P, Faruque P, Mehta-Shah N, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2020. PMID: 33002132. doi:10.1182/bloodadvances.2020002396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。